Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1 α,25-Dihydroxyvitamin D 3 ) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis
ConclusionsIn hemodialysis patients, DP001 has a longer half-life than existing vitamin D therapies and enables control of parathyroid hormone when administered every 2 –3 days on the day of dialysis. It is effective at a lower concentration maximum and area under the curve than other clinically available vitamin D compounds. DP001 may represent a therapeutic improvement over existing compounds due to rapid and extensive distribution to its target and its long h alf-life enabling sustained parathyroid hormone suppression. These studies support further evaluation of DP001 in longer-term treatment of secondary hyperparathyroidism.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Calcium | Chronic Kidney Disease | Dialysis | Drugs & Pharmacology | Electrocardiogram | Hemodialysis | Hormones | Hyperparathyroidism | Laboratory Medicine | Phosphorus | Study | Urology & Nephrology | Vitamin D | Vitamins